Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial.

J Clin Oncol · 2026 · PMC12736403 · PMID 41115255

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Knowledge Generated Adding carboplatin to standard taxane-anthracycline neoadjuvant chemotherapy significantly increased the overall survival (OS) and showed a trend toward improvement in event-free survival (EFS).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.